Everything below concerns prothymosin alpha. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
In 1957, Boyd Orr served as president of the Second International Humanist Congress, and contributed to the 1968 volume The Humanist Outlook alongside many other prominent humanists. In 1960 Boyd Orr was elected the first president of the World Academy of Art and Science, which was set up by eminent scientists of the day concerned about the potential misuse of scientific discoveries, most especially nuclear weapons. Along with Albert Einstein, Orr was one of the sponsors of the Peoples' World Convention (PWC), also known as Peoples' World Constituent Assembly (PWCA), which took place in 1950–51 at Palais Electoral, Geneva, Switzerland. He was also one of the signatories of the agreement to convene a convention for drafting a world constitution. As a result, for the first time in human history, a World Constituent Assembly convened to draft and adopt the Constitution for the Federation of Earth. Boyd Orr was a member of Bertrand Russell's Who Killed Kennedy? Committee which challenged the official version of the assassination of John F. Kennedy.
Early attempts to create alien-human hybrids were pioneered by German and Japanese scientists shortly after World War II, and for some time during the Cold War. However, these often met with failure, and the Syndicate started to rely more on their own scientists. According to the Alien Bounty Hunter, in the 1950s, Soviet geneticists found a unique genetic anomaly within identical twins. The Colonists and Syndicate scientists used this to eventually develop human clones with alien elements and partial hybrids, but they were still ultimately inferior. Hybrids of this type include Samantha Mulder, Kurt Crawford, the Gregors, Ernest Calderon, and Dr. William Secare. Child and adult versions of Samantha and Kurt are also seen. These clones have the same caustic greenish blood of the aliens, have greater muscular strength and higher physical endurance levels than most normal humans, and can breathe underwater. In addition to their intended use by the alien colonists, the Syndicate is occasionally seen using these clones to perform various tasks, such as research and physical labor. The pinnacle of the project is Cassandra Spender (Veronica Cartwright), mother of Jeffrey Spender (Chris Owens) and ex-wife of The Smoking Man. Cassandra is a hybrid created through a process other than cloning, and worked on by both the Syndicate and the aliens themselves, although the exact methods used to transform her are never fully revealed. The experiment presumably began when she, along with other family members of the Syndicate, were turned over to the colonists in 1973.
SPR curves usually show a strong minimum. With the use of a combined chromium-gold film or other carefully chosen material combinations a sharp resonance maximum can be observed when exciting a surface plasmon in the Kretschmann configuration. This may be useful in sensors applications where a strong and sharp resonance above noise is required and less heat is desired at the surface.
Sources: en.wikipedia.org
Evidence for a "virus first" or "virus world" hypothesis, which may support theories of the RNA world, was suggested in 2015. One of the difficulties for the study of the origins of viruses is their high rate of mutation; this is particularly the case in RNA retroviruses like HIV. A 2015 study compared protein fold structures across different branches of the tree of life, where researchers can reconstruct the evolutionary histories of the folds and of the organisms whose genomes code for those folds. They argue that protein folds are better markers of ancient events as their three-dimensional structures can be maintained even as the sequences that code for those begin to change. Thus, the viral protein repertoire retain traces of ancient evolutionary history that can be recovered using advanced bioinformatics approaches. Those researchers think that "the prolonged pressure of genome and particle size reduction eventually reduced virocells into modern viruses (identified by the complete loss of cellular makeup), meanwhile other coexisting cellular lineages diversified into modern cells." The data suggest that viruses originated from ancient cells that co-existed with the ancestors of modern cells. These ancient cells likely contained segmented RNA genomes. A computational model (2015) has shown that virus capsids may have originated in the RNA world and served as a means of horizontal transfer between replicator communities.
The densities of the two phases must also be sufficiently different so that the phases will move past each other in the column. Many DCCC solvent systems contain both chloroform and water. The solvent system used in the seminal publication was made from chloroform, acetic acid, and aqueous 0.1 M hydrochloric acid. Many subsequent solvents systems were made with chloroform, methanol, and water which is sometimes represented as a ChMWat solvent system. Solvent systems formulated with ''n''-butanol, water and a modifier such as acetic acid, pyridine or n-propanol have also enjoyed some success in DCCC. In some cases, non-aqueous biphasic solvent systems such as acetonitrile and methanol have been utilized. The main difference between DCCC and other types of countercurrent chromatography techniques is that there is no vigorous mixing of phases to enhance the mass transfer of compounds that allows them to distribute between the two phases. In 1951 Kies and Davis described an apparatus similar to the DCCC. They created a series of open tubes that were arranged in a cascade to either drip a more dense phase through a less dense stationary phase or, conversely, a less dense phase could be introduced into the bottom of the tube to dribble through the more dense phase. In 1954, a fractionation column was introduced by Kepes the resembled a CCC column divided into chambers with perforated plastic disks. Similar DCCC-type instruments have been created by A. E. Kostanyan and collaborators which employ vertical columns that are divided into partitions with porous disks.
One of these first-generation IUDs was the Dalkon Shield, whose poor design caused bacterial infection and led to thousands of lawsuits. Although it was removed from the market, the Dalkon Shield had a lasting, negative impact on IUD use and reputation in the United States. The invention of the copper IUD in the 1960s introduced the capital T-shaped design used by most modern IUDs. U.S. physician Howard Tatum determined this shape would work better with the space of the uterine cavity. He predicted this would reduce rates of IUD expulsion. Further, Tatum and Chilean physician Jaime Zipper discovered that copper could be an effective spermicide and developed the first copper IUD. Improvements by Tatum led to the creation of the TCu380A (ParaGard), which is the preferred copper IUD since 1997. The hormonal IUD was also invented in the 1960s and 1970s with the goal of mitigating the increased menstrual bleeding associated with copper and inert IUDs. The first model, Progestasert, lasted for one year of use and was quickly discontinued. The Mirena hormonal IUD was released in 1976.
Office for National Statistics data for the year up to June 2023 shows fewer UK births than deaths over a 12-month period for the first time since the 1970s, with 16,300 fewer births occurring, while net migration increased the population by 662,400 to an estimated 68,265,200. Housing and planning minister, Matthew Pennycook, is referred to the parliamentary commissioner for standards for not revealing his close relationship with the author of the Institute for Fiscal Studies paper which Labour ministers have used as evidence to support their introduction of 20% value-added tax (VAT) on private school fees. 9 October – The All England Club announces it will adopt electronic line calling from 2025, meaning line judges will disappear from the Wimbledon Championships. 10 October A new King Charles III heraldic Coat of Arms, alongside the new Lesser Arms, used by the UK government, both by artist Timothy Noad are officially unveiled. A further 65 women are reported to have contacted the BBC regarding sexual abuse by the late former Harrods owner Mohamed Al-Fayed. The Prince and Princess of Wales visit Southport, where they meet the families of the three children killed in the July stabbing. It is the Princess's first public engagement since her cancer treatment. A technical fault with the BBC Weather website and app leads to incorrect forecasts of hurricane winds in the UK and internationally, with one forecast predicting winds of 13,508 mph in London.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.